

Global HIV Vaccine Market & Clinical Trial Outlook 2022

<https://marketpublishers.com/r/G243C9672F8EN.html>

Date: November 2016

Pages: 200

Price: US\$ 2,000.00 (Single User License)

ID: G243C9672F8EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global HIV Vaccine Market & Clinical Trial Outlook 2022” recent report published by Kuick Research analyzes various multiple clinical and non-clinical aspects related to development of HIV vaccine worldwide. Currently there is no particular vaccine available for the treatment of HIV across the globe. There are multiple vaccines in clinical trials for the treatment and the prevention of HIV. This report gives comprehensive clinical insight on the 65 HIV Vaccines in clinical trials and analyzes all clinical parameters involved in the development of HIV Vaccine. Report analyzes multiple approaches in the development of the HIV vaccine and lists decisive factors responsible for the commercialization of HIV vaccines.

Worldwide, around 35 Million people are currently infected with the HIV and about 30 Million people died because of the AIDS infection since the beginning of the epidemic. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways of immune system which needs to respond against the HIV infection.

Vaccines are among the most powerful and cost-effective disease prevention tools. A vaccine that could prevent the HIV infection or stop the development of the disease would greatly support in the fight against the AIDS disease. Vaccines have been crucial in worldwide smallpox elimination efforts, have nearly eliminated polio and have drastically reduced the incidence of infectious diseases like measles and pertussis in the US. However, the question is arising that whether HIV vaccine should be developed for a single strain or it should be designed for varied strain structures. The whole aim is

to provide the better medication for the eradication of the virus by any means.

There are also questions about how an HIV vaccine would protect the individuals and the vaccine might not be able to actually prevent the infection, but could stop or delay progression to disease, or simply reduce the infectiousness of people who do become infected with HIV. HIV prevention education and counseling are important constituents of vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral prevention programs.

The successful development of a preventive HIV vaccine will almost positively depend upon the involvement of both the private and public sectors from around the world. Currently, no one government or company has the resources and encouragement to take on the challenge for developing an HIV vaccine alone. Within the public sector, the development of an HIV vaccine is important for a number of different agencies, which includes the concerns in health, economic development, and international development.

“Global HIV Vaccine Market & Clinical Trial Outlook 2022” Report Highlights:

Introduction to Human Immunodeficiency Virus (HIV) Vaccines

HIV Vaccine Development Process

Modified Approaches for HIV Vaccine Development

HIV Drugs Taxonomy & Resistance

Decisive Factors for Commercialization of HIV Vaccines

Global HIV Vaccine Clinical Pipeline by Company, Indication & Phase

Global HIV Vaccine Clinical Pipeline: 65 Vaccines

Contents

1. INTRODUCTION TO HUMAN IMMUNODEFICIENCY VIRUS (HIV) VACCINES

- 1.1 Overview
- 1.2 Antiquity of HIV Vaccine

2. NEED FOR THE DEVELOPMENT OF HIV VACCINE

3. PRIMER OF HIV INSIDE THE BODY

- 3.1 Inclusion of HIV Virus into the System
- 3.2 Interaction of HIV with Host
- 3.3 Eradication of HIV Virus

4. HIV VACCINE DEVELOPMENT PROCESS

- 4.1 Introduction
 - 4.1.1 Classification of HIV Virus
 - 4.1.2 Structure of HIV Virus
- 4.2 HIV Vaccine Construct Methodologies
 - 4.2.1 Live Attenuated Vaccine
 - 4.2.2 Synthetic Peptide Vaccines
 - 4.2.3 Inactivated Vaccines
 - 4.2.4 DNA Vaccine
 - 4.2.5 Recombinant Vector Vaccine

5. MODIFIED APPROACHES FOR HIV VACCINE DEVELOPMENT

- 5.1 HIV Vaccine Expansion by Computer Aided Drug Design
- 5.2 Genetic Variety Attentions for Vaccine Design
- 5.3 Virus like Particles Approach for the HIV Vaccine Production
- 5.4 T-cell based Approach for HIV Vaccine

6. PROPHYLACTIC & THERAPEUTIC HIV VACCINE

- 6.1 Prophylactic HIV Vaccine
 - 6.1.1 Pre Exposure Prophylaxis
 - 6.1.2 Post Exposure Prophylaxis (PEP)

6.2 Therapeutic HIV Vaccine

7. HIV DRUGS TAXONOMY & RESISTANCE

7.1 Categorization of the Drugs

7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)

7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

7.1.3 Protease Inhibitors

7.1.4 Fusion Inhibitors

7.2 Contrivance of HIV Drug Resistance

7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors

7.2.3 Resistance to Protease Inhibitors

7.2.4 Resistance to Fusion Inhibitors

8. DECISIVE FACTORS FOR COMMERCIALIZATION OF HIV VACCINES

8.1 Efficacy

8.2 Controlled Transmission

8.3 Relapse

8.4 Economical

8.5 Manufacturing Scalability

9. GLOBAL HIV VACCINE MARKET OUTLOOK

9.1 Overview

9.2 Current Market Scenario

9.3 Incidence & Prevalence

9.4 Funding Scenario for HIV Vaccine

10. GLOBAL HIV VACCINE CLINICAL PIPELINE OVERVIEW

11. GLOBAL HIV VACCINE MARKET DYNAMICS

11.1 Favorable Market Parameters

11.2 Commercialization Challenges

12. GLOBAL HIV VACCINE MARKET FUTURE OUTLOOK

13. GLOBAL HIV VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 13.1 Research
- 13.2 Preclinical
- 13.3 Clinical
- 13.4 Phase-I
- 13.5 Phase-I/II
- 13.6 Phase-II
- 13.7 Phase-III
- 13.8 Preregistration

14. COMPETITIVE LANDSCAPE

- 14.1 AlphaVax
- 14.2 Antigen Express
- 14.3 Argo Therapeutics
- 14.4 Bionor Pharmaceuticals
- 14.5 Celldex Therapeutics
- 14.6 FIT Biotech
- 14.7 Crucell Pharmaceutical
- 14.8 GeneCure
- 14.9 Genetic Immunity
- 14.10 GenVec
- 14.11 GeoVax Labs
- 14.12 Glaxo Smithkline
- 14.13 Immune Response BioPharma
- 14.14 Inovio Pharmaceuticals
- 14.15 Novartis
- 14.16 Oncolys Biopharma
- 14.17 PaxVax
- 14.18 Profectus Biosciences
- 14.19 Sanofi
- 14.20 TVAX Biomedical

List Of Figures

LIST OF FIGURES

- Figure 1-1: Stages of HIV Infection
- Figure 1-2: History of HIV
- Figure 3-1: Modes of Transmission of HIV Virus into the System
- Figure 3-2: Life Cycle of HIV Virus inside the Host Cell
- Figure 4-1: Structure of HIV Virus
- Figure 4-2: Approaches to Design an AIDS Vaccine
- Figure 5-1: Modified Approaches for HIV Vaccine Development
- Figure 7-1: Categories of Antiretroviral Drugs
- Figure 7-2: Mechanism of Resistance to Nucleoside Reverse Transcriptase Inhibitors
- Figure 7-3: Usage of Resistance to Non-Nucleoside Reverse Transcriptase Inhibitor
- Figure 7-4: Resistance to Protease Inhibitors
- Figure 7-5: Resistance to Fusion Inhibitors
- Figure 8-1: Requirements for Successful Commercialization of HIV Vaccines
- Figure 9-1: Global HIV/AIDS Therapeutics Market (US\$ Billion), 2012-2022
- Figure 9-2: Global - Truvada Sales (US\$ Million), 2011-2015
- Figure 9-3: Global – Atripla Sales (US\$ Million), 2011-2015
- Figure 9-4: Global – Prezista Sales (US\$ Million), 2011-2015
- Figure 9-5: Global – Complera/Eviplera Sales (US\$ Million), 2011-2015
- Figure 9-6: Global – Sustiva Sales (US\$ Million), 2011-2015
- Figure 9-7: Global – Sustiva Sales (US\$ Million), 2011-2015
- Figure 9-8: Global – Viread Sales (US\$ Million), 2011-2015
- Figure 9-9: Global – Epzicom Sales (US\$ Million), 2011-2015
- Figure 9-10: Global – Kaletra Sales (US\$ Million), 2011-2015
- Figure 9-11: Global – Combivir Sales (US\$ Million), 2011-2015
- Figure 9-12: Global - HIV Incidence (Million), 2015
- Figure 9-13: Global - People Living with HIV (Million), 2011-2015
- Figure 9-14: Global – New HIV Infections (Million), 2011-2015
- Figure 9-15: Global –HIV Deaths (Million), 2011-2015
- Figure 9-16: Global – People Living with HIV On Antiretroviral Therapy (Million), 2011-2015
- Figure 9-17: US – HIV Incidence (Million), 2015
- Figure 9-18: Asia Pacific-HIV Incidence (Million), 2015
- Figure 9-19: India - HIV Incidence (Million), 2015
- Figure 9-20: Europe - HIV Incidence (Million), 2015
- Figure 9-21: UK - HIV Incidence (Millions), 2015

Figure 9-22: South Africa - HIV Incidence (Million), 2015

Figure 9-23: Global - HIV prevention R&D Investments by Sector, 2015

Figure 9-24: US - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015

Figure 9-25: US - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015

Figure 9-26: Europe - Public Sector & Other Investments in HIV prevention R&D (%), 2011 to 2015

Figure 9-27: Europe - Public Sector Investments in HIV Prevention R&D by Technology (%), 2011 to 2015

Figure 9-28: Global - Investments in R&D Prevention by Top Philanthropic Funders (US\$ Million)

Figure 9-29: Top Public Sector Investing in HIV Prevention R&D, 2012–2015 (US\$ Million)

Figure 9-30: HIV Vaccines by Country (%), 2014

Figure 9-31: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%)

Figure 10-1: Global HIV - Vaccine Pipeline by Phase (%), 2016 to 2022

Figure 10-2: Global HIV - Vaccine Pipeline by Phase (Numbers), 2016 to 2022

Figure 10-3: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%), 2016 to 2022

Figure 10-4: Global HIV - Vaccine Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Numbers), 2016 to 2022

Figure 11-1: Driving Forces of HIV Vaccine Market

Figure 11-2: Challenges to the HIV Vaccine Development

Figure 14-1: AlphaVax Clinical Pipeline

Figure 14-2: Bionor Pharma Clinical Pipeline

Figure 14-3: Profectus BioSciences Clinical Pipeline

Figure 14-4: TVAX Biomedical Clinical Pipeline

I would like to order

Product name: Global HIV Vaccine Market & Clinical Trial Outlook 2022

Product link: <https://marketpublishers.com/r/G243C9672F8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G243C9672F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970